Avidity Biosciences, Inc. financial data

Symbol
RNA on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1270% % -6.5%
Debt-to-equity 12% % -5.9%
Return On Equity -38% % -36%
Return On Assets -34% % -37%
Operating Margin -2935% % 8.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 150,675,742 shares 26%
Common Stock, Shares, Outstanding 146,771,000 shares 23%
Entity Public Float $4,400,000,000 USD 442%
Common Stock, Value, Issued $15,000 USD 25%
Weighted Average Number of Shares Outstanding, Basic 137,895,000 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 137,895,000 shares 12%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $20,868,000 USD 106%
Research and Development Expense $488,187,000 USD 87%
General and Administrative Expense $145,135,000 USD 96%
Operating Income (Loss) $612,454,000 USD -89%
Nonoperating Income (Expense) $62,668,000 USD 42%
Net Income (Loss) Attributable to Parent $549,786,000 USD -96%
Earnings Per Share, Basic -4 USD/shares -45%
Earnings Per Share, Diluted -4 USD/shares -45%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $350,158,000 USD -5.4%
Cash, Cash Equivalents, and Short-term Investments $1,200,000,000 USD -7.7%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD -100%
Other Assets, Current $59,992,000 USD
Assets, Current $1,966,017,000 USD 21%
Property, Plant and Equipment, Net $21,504,000 USD 127%
Operating Lease, Right-of-Use Asset $52,848,000 USD 739%
Other Assets, Noncurrent $91,042,000 USD 28530%
Assets $2,134,209,000 USD 30%
Accounts Payable, Current $9,626,000 USD 26%
Contract with Customer, Liability, Current $19,123,000 USD -2.7%
Liabilities, Current $169,879,000 USD 86%
Contract with Customer, Liability, Noncurrent $32,066,000 USD -24%
Operating Lease, Liability, Noncurrent $45,999,000 USD 1111%
Liabilities $247,944,000 USD 80%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,768,000 USD -75%
Retained Earnings (Accumulated Deficit) $1,340,596,000 USD -70%
Stockholders' Equity Attributable to Parent $1,886,265,000 USD 25%
Liabilities and Equity $2,134,209,000 USD 30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $124,829,000 USD -77%
Net Cash Provided by (Used in) Financing Activities $1,937,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $157,188,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 146,771,000 shares 23%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $34,335,000 USD -88%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $352,956,000 USD -5.4%
Deferred Tax Assets, Valuation Allowance $271,636,000 USD 57%
Deferred Tax Assets, Gross $272,830,000 USD 56%
Operating Lease, Liability $49,966,000 USD
Depreciation $3,420,000 USD 29%
Payments to Acquire Property, Plant, and Equipment $3,753,000 USD 310%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $555,119,000 USD -104%
Lessee, Operating Lease, Liability, to be Paid $84,084,000 USD
Property, Plant and Equipment, Gross $31,951,000 USD 91%
Operating Lease, Liability, Current $3,967,000 USD 4.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $7,259,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $8,323,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $34,118,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $9,230,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $83,371,000 USD 15%
Unrecognized Tax Benefits $22,159,000 USD 101%
Lessee, Operating Lease, Liability, to be Paid, Year Four $9,506,000 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,194,000 USD -39%
Share-based Payment Arrangement, Expense $68,572,000 USD 46%